Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-04-18

AUTHORS

Nacho Castejón, Joseph C. Cappelleri, Jesús Cuervo, Kathryn Lang, Priyanka Mehta, Ruth Mokgokong, Carla Mamolo

ABSTRACT

BACKGROUND: Health state (HS) utility values for patients with acute myeloid leukemia (AML), a hematological malignancy, are not available in the United Kingdom (UK). This study aims to develop clinically sound HSs for previously untreated patients with AML and to assign utility values based on preferences of the general UK population. METHODS: This study was conducted in the UK and comprised 2 stages. During the first stage, AML HSs were drafted based on evidence from a literature review of AML clinical and health-related quality-of-life studies (published January 2000-June 2016) and patient-reported outcome measures previously used in this population. A panel of UK hematologists with AML experience validated the clinical relevance and accuracy of the HSs. During the second stage, validated HSs were valued in an elicitation survey with a representative UK population sample using the time trade-off (TTO) method. Descriptive statistics and bivariate tests were obtained and performed. RESULTS: A total of eight HSs were developed and clinically validated, including treatment with chemotherapy, consolidation therapy, transplant, graft-vs-host disease (GvHD), remission, relapse, refractory, and functionally cured. In total, 125 adults participated (mean age, 49.6 years [range, 18-87 years], 52.8% female). Mean (95% confidence interval [CI]) TTO preference values (n = 120), ranked from lowest (worst HS) to highest (best HS) were as follows: refractory - 0.11 (- 0.21 to - 0.01), relapse 0.10 (0.00-0.20), transplant 0.28 (0.20-0.37), treatment with chemotherapy 0.36 (0.28-0.43), GvHD 0.43 (0.36-0.50), consolidation 0.46 (0.40-0.53), remission 0.62 (0.57-0.67), and functionally cured 0.76 (0.72-0.79). Mean (95% CI) visual analog scale preference values followed the same rank order, ranging from 0.15 (0.13-0.17) for refractory to 0.71 (0.68-0.73) for functionally cured. CONCLUSIONS: To our knowledge, this is the first study to report utility values for AML from the UK societal perspective. Participants were able to distinguish differences in severity among AML HSs, and preference values were consistent with clinical perception of HS severity. HS preference values observed in this study may be useful in future evaluations of treatment benefit, including cost-effectiveness analyses and improved patient well-being. More... »

PAGES

66

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12955-018-0897-8

DOI

http://dx.doi.org/10.1186/s12955-018-0897-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103460430

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29669568


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Attitude to Health", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Preference", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Visual Analog Scale", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "HEOR Senior Consultant, Barrio de Abajo, \u201cLas Barcas\u201d, 33595 Celorio, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HEOR Senior Consultant, Barrio de Abajo, \u201cLas Barcas\u201d, 33595 Celorio, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castej\u00f3n", 
        "givenName": "Nacho", 
        "id": "sg:person.0634004027.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634004027.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cappelleri", 
        "givenName": "Joseph C.", 
        "id": "sg:person.01340453362.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340453362.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "LA-SER Research Espa\u00f1a, C/Condado de Trevi\u00f1o 2, Portal 1-Bajo 3, 28033 Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "LA-SER Research Espa\u00f1a, C/Condado de Trevi\u00f1o 2, Portal 1-Bajo 3, 28033 Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cuervo", 
        "givenName": "Jes\u00fas", 
        "id": "sg:person.01044512703.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044512703.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lang", 
        "givenName": "Kathryn", 
        "id": "sg:person.014242101212.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014242101212.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol Haematology Oncology Centre, University Hospitals Bristol NHS Trust, Horfield Road, Bristol, BS2 8ED UK", 
          "id": "http://www.grid.ac/institutes/grid.410421.2", 
          "name": [
            "Bristol Haematology Oncology Centre, University Hospitals Bristol NHS Trust, Horfield Road, Bristol, BS2 8ED UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehta", 
        "givenName": "Priyanka", 
        "id": "sg:person.01234111006.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234111006.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mokgokong", 
        "givenName": "Ruth", 
        "id": "sg:person.015635042212.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015635042212.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mamolo", 
        "givenName": "Carla", 
        "id": "sg:person.01025026610.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025026610.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12955-015-0377-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014095516", 
          "https://doi.org/10.1186/s12955-015-0377-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2014.332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052439105", 
          "https://doi.org/10.1038/leu.2014.332"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04-18", 
    "datePublishedReg": "2018-04-18", 
    "description": "BACKGROUND: Health state (HS) utility values for patients with acute myeloid leukemia (AML), a hematological malignancy, are not available in the United Kingdom (UK). This study aims to develop clinically sound HSs for previously untreated patients with AML and to assign utility values based on preferences of the general UK population.\nMETHODS: This study was conducted in the UK and comprised 2 stages. During the first stage, AML HSs were drafted based on evidence from a literature review of AML clinical and health-related quality-of-life studies (published January 2000-June 2016) and patient-reported outcome measures previously used in this population. A panel of UK hematologists with AML experience validated the clinical relevance and accuracy of the HSs. During the second stage, validated HSs were valued in an elicitation survey with a representative UK population sample using the time trade-off (TTO) method. Descriptive statistics and bivariate tests were obtained and performed.\nRESULTS: A total of eight HSs were developed and clinically validated, including treatment with chemotherapy, consolidation therapy, transplant, graft-vs-host disease (GvHD), remission, relapse, refractory, and functionally cured. In total, 125 adults participated (mean age, 49.6\u00a0years [range, 18-87\u00a0years], 52.8% female). Mean (95% confidence interval [CI]) TTO preference values (n\u2009=\u2009120), ranked from lowest (worst HS) to highest (best HS) were as follows: refractory -\u20090.11 (-\u20090.21 to -\u20090.01), relapse 0.10 (0.00-0.20), transplant 0.28 (0.20-0.37), treatment with chemotherapy 0.36 (0.28-0.43), GvHD 0.43 (0.36-0.50), consolidation 0.46 (0.40-0.53), remission 0.62 (0.57-0.67), and functionally cured 0.76 (0.72-0.79). Mean (95% CI) visual analog scale preference values followed the same rank order, ranging from 0.15 (0.13-0.17) for refractory to 0.71 (0.68-0.73) for functionally cured.\nCONCLUSIONS: To our knowledge, this is the first study to report utility values for AML from the UK societal perspective. Participants were able to distinguish differences in severity among AML HSs, and preference values were consistent with clinical perception of HS severity. HS preference values observed in this study may be useful in future evaluations of treatment benefit, including cost-effectiveness analyses and improved patient well-being.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12955-018-0897-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031326", 
        "issn": [
          "1477-7525"
        ], 
        "name": "Health and Quality of Life Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "acute myeloid leukemia", 
      "myeloid leukemia", 
      "patient-reported outcome measures", 
      "health-related quality", 
      "general UK population", 
      "health state utility values", 
      "UK population sample", 
      "cost-effectiveness analysis", 
      "consolidation therapy", 
      "host disease", 
      "untreated patients", 
      "treatment benefit", 
      "outcome measures", 
      "HS severity", 
      "time trade-off (TTO) method", 
      "hematological malignancies", 
      "clinical relevance", 
      "patients", 
      "societal perspective", 
      "clinical perception", 
      "UK population", 
      "utility values", 
      "same rank order", 
      "bivariate tests", 
      "population sample", 
      "health states", 
      "leukemia", 
      "treatment", 
      "descriptive statistics", 
      "severity", 
      "life studies", 
      "United Kingdom", 
      "rank order", 
      "future evaluation", 
      "total", 
      "refractory", 
      "first study", 
      "literature review", 
      "remission", 
      "chemotherapy", 
      "relapse", 
      "malignancy", 
      "transplant", 
      "therapy", 
      "graft", 
      "population", 
      "study", 
      "disease", 
      "HS", 
      "adults", 
      "stage", 
      "participants", 
      "review", 
      "evidence", 
      "elicitation survey", 
      "differences", 
      "evaluation", 
      "benefits", 
      "measures", 
      "relevance", 
      "test", 
      "trade-off method", 
      "values", 
      "panel", 
      "survey", 
      "experience", 
      "Kingdom", 
      "preferences", 
      "samples", 
      "quality", 
      "perception", 
      "knowledge", 
      "analysis", 
      "second stage", 
      "preference values", 
      "statistics", 
      "first stage", 
      "method", 
      "social preferences", 
      "perspective", 
      "state", 
      "accuracy", 
      "order", 
      "state (HS) utility values", 
      "AML HSs", 
      "panel of UK", 
      "AML experience", 
      "representative UK population sample", 
      "Mean (95% confidence interval [CI]) TTO preference values", 
      "TTO preference values", 
      "Mean (95% CI) visual analog scale preference values", 
      "visual analog scale preference values", 
      "analog scale preference values", 
      "scale preference values", 
      "UK societal perspective", 
      "HS preference values"
    ], 
    "name": "Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom", 
    "pagination": "66", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103460430"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12955-018-0897-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29669568"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12955-018-0897-8", 
      "https://app.dimensions.ai/details/publication/pub.1103460430"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_778.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12955-018-0897-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12955-018-0897-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12955-018-0897-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12955-018-0897-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12955-018-0897-8'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      22 PREDICATES      141 URIs      131 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12955-018-0897-8 schema:about N074b7d55c0a94da781b605f0513d2130
2 N09c7d5100dae42fdb7fa12e2b1599952
3 N2c1d05ee32c64e34b8c5ef5d9c70f35a
4 N500dc37d62bf47e285d908f73753f485
5 N6f33d3d12921422da9e29c9e6d0d6f87
6 N6f5ecbf4c23b467386e772c0e4eaae6d
7 N7bfbc8a6e8e3448f951b220f53c90110
8 N84a4152a49a8495baabb5fca3adc8f41
9 N8eaaf4a7919940cd8fc2465fffa5bea7
10 N9f494b23bac54cda8ff7c3655ed70dac
11 Na3eee2a1c45e4113bd380060e4653128
12 Nac0c5c318bd848a195b470ea1bb80d5a
13 Nb03d57ead20843fb8efcd3480ebd395e
14 Nb4a6453b2a8d4b88b0d25d0ff6161b7b
15 Nefbae98ee4a845c7a43b178280926c70
16 Nf1e5bac18a77444d8ef30043c0b89ef2
17 Nf7e528d54b4e49c38b81e46258b1571e
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N70e242ad33764deaadb0204bcd7a8d78
21 schema:citation sg:pub.10.1038/leu.2014.332
22 sg:pub.10.1186/s12955-015-0377-3
23 schema:datePublished 2018-04-18
24 schema:datePublishedReg 2018-04-18
25 schema:description BACKGROUND: Health state (HS) utility values for patients with acute myeloid leukemia (AML), a hematological malignancy, are not available in the United Kingdom (UK). This study aims to develop clinically sound HSs for previously untreated patients with AML and to assign utility values based on preferences of the general UK population. METHODS: This study was conducted in the UK and comprised 2 stages. During the first stage, AML HSs were drafted based on evidence from a literature review of AML clinical and health-related quality-of-life studies (published January 2000-June 2016) and patient-reported outcome measures previously used in this population. A panel of UK hematologists with AML experience validated the clinical relevance and accuracy of the HSs. During the second stage, validated HSs were valued in an elicitation survey with a representative UK population sample using the time trade-off (TTO) method. Descriptive statistics and bivariate tests were obtained and performed. RESULTS: A total of eight HSs were developed and clinically validated, including treatment with chemotherapy, consolidation therapy, transplant, graft-vs-host disease (GvHD), remission, relapse, refractory, and functionally cured. In total, 125 adults participated (mean age, 49.6 years [range, 18-87 years], 52.8% female). Mean (95% confidence interval [CI]) TTO preference values (n = 120), ranked from lowest (worst HS) to highest (best HS) were as follows: refractory - 0.11 (- 0.21 to - 0.01), relapse 0.10 (0.00-0.20), transplant 0.28 (0.20-0.37), treatment with chemotherapy 0.36 (0.28-0.43), GvHD 0.43 (0.36-0.50), consolidation 0.46 (0.40-0.53), remission 0.62 (0.57-0.67), and functionally cured 0.76 (0.72-0.79). Mean (95% CI) visual analog scale preference values followed the same rank order, ranging from 0.15 (0.13-0.17) for refractory to 0.71 (0.68-0.73) for functionally cured. CONCLUSIONS: To our knowledge, this is the first study to report utility values for AML from the UK societal perspective. Participants were able to distinguish differences in severity among AML HSs, and preference values were consistent with clinical perception of HS severity. HS preference values observed in this study may be useful in future evaluations of treatment benefit, including cost-effectiveness analyses and improved patient well-being.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N360b66b35b5c4a61bc509139de222fb6
30 N6473850c20e84ab7b78713c26cbd340e
31 sg:journal.1031326
32 schema:keywords AML HSs
33 AML experience
34 HS
35 HS preference values
36 HS severity
37 Kingdom
38 Mean (95% CI) visual analog scale preference values
39 Mean (95% confidence interval [CI]) TTO preference values
40 TTO preference values
41 UK population
42 UK population sample
43 UK societal perspective
44 United Kingdom
45 accuracy
46 acute myeloid leukemia
47 adults
48 analog scale preference values
49 analysis
50 benefits
51 bivariate tests
52 chemotherapy
53 clinical perception
54 clinical relevance
55 consolidation therapy
56 cost-effectiveness analysis
57 descriptive statistics
58 differences
59 disease
60 elicitation survey
61 evaluation
62 evidence
63 experience
64 first stage
65 first study
66 future evaluation
67 general UK population
68 graft
69 health state utility values
70 health states
71 health-related quality
72 hematological malignancies
73 host disease
74 knowledge
75 leukemia
76 life studies
77 literature review
78 malignancy
79 measures
80 method
81 myeloid leukemia
82 order
83 outcome measures
84 panel
85 panel of UK
86 participants
87 patient-reported outcome measures
88 patients
89 perception
90 perspective
91 population
92 population sample
93 preference values
94 preferences
95 quality
96 rank order
97 refractory
98 relapse
99 relevance
100 remission
101 representative UK population sample
102 review
103 same rank order
104 samples
105 scale preference values
106 second stage
107 severity
108 social preferences
109 societal perspective
110 stage
111 state
112 state (HS) utility values
113 statistics
114 study
115 survey
116 test
117 therapy
118 time trade-off (TTO) method
119 total
120 trade-off method
121 transplant
122 treatment
123 treatment benefit
124 untreated patients
125 utility values
126 values
127 visual analog scale preference values
128 schema:name Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom
129 schema:pagination 66
130 schema:productId N3ad688c25a5b4ebd828e255504bf5a2f
131 Nc0868c8bf74f4ba1b11fb703801cfff0
132 Ndc95edf29a8b4203a4ff7a75e0be686f
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103460430
134 https://doi.org/10.1186/s12955-018-0897-8
135 schema:sdDatePublished 2021-12-01T19:42
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher N0246230f49ae427884546ea3285e47f8
138 schema:url https://doi.org/10.1186/s12955-018-0897-8
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N0246230f49ae427884546ea3285e47f8 schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 N074b7d55c0a94da781b605f0513d2130 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Male
146 rdf:type schema:DefinedTerm
147 N09c7d5100dae42fdb7fa12e2b1599952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Cross-Sectional Studies
149 rdf:type schema:DefinedTerm
150 N29ce90fa34c248098126ddefe1e75286 rdf:first sg:person.01234111006.46
151 rdf:rest N7124695d27014addb9998caefb84cd53
152 N2c1d05ee32c64e34b8c5ef5d9c70f35a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Sex Factors
154 rdf:type schema:DefinedTerm
155 N360b66b35b5c4a61bc509139de222fb6 schema:volumeNumber 16
156 rdf:type schema:PublicationVolume
157 N3ad688c25a5b4ebd828e255504bf5a2f schema:name doi
158 schema:value 10.1186/s12955-018-0897-8
159 rdf:type schema:PropertyValue
160 N4070e330bdf942d9b677411612bea4e6 rdf:first sg:person.01340453362.44
161 rdf:rest Nf1976e88cb4d4a729ca9908f51268a0d
162 N500dc37d62bf47e285d908f73753f485 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Attitude to Health
164 rdf:type schema:DefinedTerm
165 N6122ce2698a545799a5150f0491573c5 rdf:first sg:person.01025026610.44
166 rdf:rest rdf:nil
167 N6473850c20e84ab7b78713c26cbd340e schema:issueNumber 1
168 rdf:type schema:PublicationIssue
169 N6f33d3d12921422da9e29c9e6d0d6f87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Humans
171 rdf:type schema:DefinedTerm
172 N6f5ecbf4c23b467386e772c0e4eaae6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Patient Preference
174 rdf:type schema:DefinedTerm
175 N70e242ad33764deaadb0204bcd7a8d78 rdf:first sg:person.0634004027.26
176 rdf:rest N4070e330bdf942d9b677411612bea4e6
177 N7124695d27014addb9998caefb84cd53 rdf:first sg:person.015635042212.43
178 rdf:rest N6122ce2698a545799a5150f0491573c5
179 N741aae71f2c140a08261eab472ec7cd1 rdf:first sg:person.014242101212.93
180 rdf:rest N29ce90fa34c248098126ddefe1e75286
181 N7bfbc8a6e8e3448f951b220f53c90110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Leukemia, Myeloid, Acute
183 rdf:type schema:DefinedTerm
184 N84a4152a49a8495baabb5fca3adc8f41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name United Kingdom
186 rdf:type schema:DefinedTerm
187 N8eaaf4a7919940cd8fc2465fffa5bea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Middle Aged
189 rdf:type schema:DefinedTerm
190 N9f494b23bac54cda8ff7c3655ed70dac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Young Adult
192 rdf:type schema:DefinedTerm
193 Na3eee2a1c45e4113bd380060e4653128 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Visual Analog Scale
195 rdf:type schema:DefinedTerm
196 Nac0c5c318bd848a195b470ea1bb80d5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Surveys and Questionnaires
198 rdf:type schema:DefinedTerm
199 Nb03d57ead20843fb8efcd3480ebd395e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Aged, 80 and over
201 rdf:type schema:DefinedTerm
202 Nb4a6453b2a8d4b88b0d25d0ff6161b7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Quality of Life
204 rdf:type schema:DefinedTerm
205 Nc0868c8bf74f4ba1b11fb703801cfff0 schema:name dimensions_id
206 schema:value pub.1103460430
207 rdf:type schema:PropertyValue
208 Ndc95edf29a8b4203a4ff7a75e0be686f schema:name pubmed_id
209 schema:value 29669568
210 rdf:type schema:PropertyValue
211 Nefbae98ee4a845c7a43b178280926c70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Aged
213 rdf:type schema:DefinedTerm
214 Nf1976e88cb4d4a729ca9908f51268a0d rdf:first sg:person.01044512703.79
215 rdf:rest N741aae71f2c140a08261eab472ec7cd1
216 Nf1e5bac18a77444d8ef30043c0b89ef2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Female
218 rdf:type schema:DefinedTerm
219 Nf7e528d54b4e49c38b81e46258b1571e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Adult
221 rdf:type schema:DefinedTerm
222 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
223 schema:name Medical and Health Sciences
224 rdf:type schema:DefinedTerm
225 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
226 schema:name Oncology and Carcinogenesis
227 rdf:type schema:DefinedTerm
228 sg:journal.1031326 schema:issn 1477-7525
229 schema:name Health and Quality of Life Outcomes
230 schema:publisher Springer Nature
231 rdf:type schema:Periodical
232 sg:person.01025026610.44 schema:affiliation grid-institutes:grid.410513.2
233 schema:familyName Mamolo
234 schema:givenName Carla
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025026610.44
236 rdf:type schema:Person
237 sg:person.01044512703.79 schema:affiliation grid-institutes:None
238 schema:familyName Cuervo
239 schema:givenName Jesús
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044512703.79
241 rdf:type schema:Person
242 sg:person.01234111006.46 schema:affiliation grid-institutes:grid.410421.2
243 schema:familyName Mehta
244 schema:givenName Priyanka
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234111006.46
246 rdf:type schema:Person
247 sg:person.01340453362.44 schema:affiliation grid-institutes:grid.410513.2
248 schema:familyName Cappelleri
249 schema:givenName Joseph C.
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340453362.44
251 rdf:type schema:Person
252 sg:person.014242101212.93 schema:affiliation grid-institutes:grid.418566.8
253 schema:familyName Lang
254 schema:givenName Kathryn
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014242101212.93
256 rdf:type schema:Person
257 sg:person.015635042212.43 schema:affiliation grid-institutes:grid.418566.8
258 schema:familyName Mokgokong
259 schema:givenName Ruth
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015635042212.43
261 rdf:type schema:Person
262 sg:person.0634004027.26 schema:affiliation grid-institutes:None
263 schema:familyName Castejón
264 schema:givenName Nacho
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634004027.26
266 rdf:type schema:Person
267 sg:pub.10.1038/leu.2014.332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052439105
268 https://doi.org/10.1038/leu.2014.332
269 rdf:type schema:CreativeWork
270 sg:pub.10.1186/s12955-015-0377-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014095516
271 https://doi.org/10.1186/s12955-015-0377-3
272 rdf:type schema:CreativeWork
273 grid-institutes:None schema:alternateName HEOR Senior Consultant, Barrio de Abajo, “Las Barcas”, 33595 Celorio, Spain
274 LA-SER Research España, C/Condado de Treviño 2, Portal 1-Bajo 3, 28033 Madrid, Spain
275 schema:name HEOR Senior Consultant, Barrio de Abajo, “Las Barcas”, 33595 Celorio, Spain
276 LA-SER Research España, C/Condado de Treviño 2, Portal 1-Bajo 3, 28033 Madrid, Spain
277 rdf:type schema:Organization
278 grid-institutes:grid.410421.2 schema:alternateName Bristol Haematology Oncology Centre, University Hospitals Bristol NHS Trust, Horfield Road, Bristol, BS2 8ED UK
279 schema:name Bristol Haematology Oncology Centre, University Hospitals Bristol NHS Trust, Horfield Road, Bristol, BS2 8ED UK
280 rdf:type schema:Organization
281 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA
282 schema:name Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340 USA
283 rdf:type schema:Organization
284 grid-institutes:grid.418566.8 schema:alternateName Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK
285 schema:name Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS UK
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...